Updated Jul 16, 2026 · Last SEC filing 2026-06-29
Tarsus Pharmaceuticals, Inc. (TARS) has filed 18 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-29. 4 Form 8-K material event filings were reported by TARS in the last 90 days. 4 Form 144 notices of proposed sale were filed for TARS stock. InsiderAlpha tracks every TARS SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001819790 |
|---|
| Form 4 filings (90d) | 18 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 4 |
| Latest Form 4 filing | 2026-06-29 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Azamian Bobak R. | President/CEO and Board Chair | S — Open-market sale | 4.6K | $61.24 | $281K | SEC | |
| Azamian Bobak R. | President/CEO and Board Chair | S — Open-market sale | 5.4K | $61.81 | $335K | SEC | |
| Farrow Jeffrey S | See Remarks | S — Open-market sale | 14.4K | $60.95 | $877K | SEC | |
| LINK WILLIAM J PHD | Director | S — Open-market sale | 1.9K | $62.94 | $121K | SEC | |
| Farrow Jeffrey S | See Remarks | M — Option exercise | 27.9K | — | — | SEC | |
| Goodrich Katherine | Director | S — Open-market sale | 3.0K | $62.08 | $183K | SEC | |
| LINK WILLIAM J PHD | Director | S — Open-market sale | 10.6K | $61.97 | $655K | SEC | |
| CHAUDHURI BHASKAR | Director | M — Option exercise | 3.0K | — | — | SEC | |
| YARNO WENDY L | Director | M — Option exercise | 3.0K | — | — | SEC | |
| LINK WILLIAM J PHD | Director | M — Option exercise | 3.0K | — | — | SEC | |
| Morrison Scott W | Director | M — Option exercise | 3.0K | — | — | SEC | |
| Goldberg Andrew D. | Director | M — Option exercise | 3.0K | — | — | SEC | |
| Goodrich Katherine | Director | M — Option exercise | 3.0K | — | — | SEC | |
| PYOTT DAVID E I | Director | M — Option exercise | 1.4K | — | — | SEC | |
| Neervannan Seshadri | Chief Operating Officer | S — Open-market sale [10b5-1] | 3.0K | $66.75 | $200K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Tarsus Pharmaceuticals, Inc. (TARS). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| LINK WILLIAM J PHD | 7 | $776K |
| YARNO WENDY L | 5 | — |
| PYOTT DAVID E I | 5 | — |
| Goodrich Katherine | 5 | $183K |
| Morrison Scott W | 4 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in TARS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live TARS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.